Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib
将放射性标记的靶向 HER2 的单域抗体与 PARP 抑制剂奥拉帕尼联合使用,可产生临床前协同效应。
期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/s12967-025-07572-2
Dewulf, Jonatan; Navarro, Laurent; Dumauthioz, Nina; Berdal, Marion; Nagachinta, Surasa; Gaspariunaite, Vaiva; Pombo Antunes, Ana Rita; Lahoutte, Tony; Massa, Sam; Devoogdt, Nick; D'Huyvetter, Matthias